Latest news with #familybuilding
Yahoo
30-07-2025
- Business
- Yahoo
New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage
Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the results of their new national Women in the Workplace research conducted in partnership with Dynata, the world's largest first-party data company for insights, activation, and measurement. The study reveals a persistent gap between what employees want from their women's health benefits, and what employers believe they are providing. Specifically, results show that 81% of HR leaders say they're committed to advancing women's health and well-being in the workplace, but only 52% of working women believe their benefits make healthcare affordable. 'The trend of women seeking out and even changing jobs for better benefits has been a persistent one the past few years. This study proves that women know what they want, and they are raising their voices. Simultaneously, HR leaders are aware of this trend and are eager to expand their women's health benefits to get ahead in talent recruitment and retention,' said Katie Higgins, Chief Commercial Officer, Progyny. 'Where the mark in women's health benefits may be missed is with the absence of a unified benefit that provides success to both sides – covers the continuum of care for women, increases engagement, results in clinical impact, and provides cost-control.' According to the study, while most employers express a strong interest in supporting women's health, they are unknowingly falling short in delivering access to specialized care, clear benefits navigation, and the personalization employees expect, particularly across critical life stages like fertility, pregnancy, and menopause. It's not enough to simply offer a women's health benefit or access to a digital tool – the benefit needs to be designed and implemented with intention. This new research shows leading concerns among female employees include: A significant gap exists. While 83% of women say benefits that support coaching and treatment for menopause are important, only 12% say their employer does a good job in providing limits impact. Nearly one in four women (24%) who wanted to use a benefit gave up because it was too complex to understand or access. Integration matters. 83% of women and 88% of employers agree that centralized support from one place would make women's health benefits more effective. The stakes are high. 69% of benefit managers said women's health benefits are extremely important to their strategy of attracting and retaining younger employees. One employer respondent summed it up: 'I feel that the lack of dedicated resources, such as an internal women's health advocate or specialist, prevents us from delivering a truly comprehensive women's health program.' The data shows that employers need a solution that brings it all together: personalized care from top-tier specialists, built-in education, connected services, and ongoing support. 'We speak with employers who are deeply committed to supporting their workforce, but many don't know where to start and feel the goal post keeps moving, "said Higgins. 'This research highlights where employee needs are greatest and shows that offering support across the full women's health journey is now table stakes. Leading organizations aren't just keeping up with trends – they're investing strategically to improve outcomes, control costs, and retain talent.' To view the full study results and learn how Progyny can help your organization bridge the gap in family building and women's health benefits, visit About this research: 1,202 women ages 18-65; US residents; with private health insurance, employed full-time at US employers with 250 or more employees were surveyed in September 2024 with a +/- 2.9% margin of error at a 95% confidence level. 252 benefits-decision makers ages 25+ whose primary role is HR or Admin/Management, involved in health insurance or wellness benefits; work in US public/private/government businesses (excluding non-profits); company in business 1+ years) employed full-time at employers with 250 or more employees were surveyed in September 2024 with a +/- 6.3% margin of error at a 95% confidence level. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit About Dynata Dynata is the world's largest first-party data company for insights, activation and measurement. With a reach that encompasses nearly 70 million consumers and business professionals globally, and an extensive library of individual profile attributes collected through surveys, Dynata is the cornerstone for precise, trustworthy quality data. The company has built innovative data services and solutions around its robust first-party data offering to bring the voice of the customer to the entire marketing continuum — from uncovering insights to activating campaigns and measuring cross-channel marketing ROI. Dynata serves more than 6,000 market research, media and advertising agencies, publishers, consulting and investment firms and corporate customers in North America, South America, Europe and Asia-Pacific. Learn more at For Further Information, Please Contact: Media: Alexis Ford media@ Investors: James Hart investors@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Health
- Yahoo
Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA, maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging members upstream as they are being more proactive with their health. As a result, potential risks can be identified earlier, while also supporting a range of health goals, such as optimizing conception attempts or making sustainable lifestyle changes. 'The more women understand about their bodies, the more empowered they are to partner with their health providers and articulate their health status and goals. Whether you are focused on conceiving your first child or managing changing weight and sleep issues through menopause, understanding your personal data is powerful—physically and emotionally,' said Janet Choi, MD, Progyny Chief Medical Officer. 'Taking control with physiologic data from the Oura Ring further supports Progyny's focus on raising the bar and elevating health outcomes.' With the ability to continuously track key health metrics, such as sleep patterns, cycle insights, cardiovascular health, stress levels, and more, ŌURA helps women understand their bodies so they can achieve optimal health. For those trying to conceive, these insights can help pinpoint fertile windows and support reproductive planning. During perimenopause or menopause, they can help identify patterns, guide impactful lifestyle adjustments, and inform meaningful conversations with providers. When needed, care plans, including personalized recommendations around sleep, nutrition, movement, and stress to support the body's changing needs can be developed. 'Reproductive health management starts long before a doctor's visit—it begins with daily awareness of your body's patterns,' said Dorothy Kilroy, Chief Commercial Officer at ŌURA. 'By partnering with Progyny, we're bridging the gap between those daily health patterns and clinical care, helping people navigate fertility and family planning with greater clarity, confidence, and support. This collaboration brings Oura's powerful health signals into a setting where they can truly make a difference—guiding smarter care, earlier interventions, and more personalized journeys.' Oura Ring and Oura Membership will be available to Progyny clients, including employers and health plans, beginning in early 2026. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For More Information, Please Contact: Media:Alexis Fordmedia@ Investors:James Hartinvestors@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Globe and Mail
08-07-2025
- Business
- Globe and Mail
Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
Operational and Financial Flexibility Enhanced Through New Credit Facility Second Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) ('Progyny' or the 'Company'), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the 'revolver' or the 'facility') which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expected to enhance the Company's operational and financial flexibility beyond its current ability to generate significant cash flow. 'At this stage of our growth, entering into a facility is an appropriate next step to further enhance our strong financial profile and extend our market leadership, and with the favorable market conditions, we felt this was an opportune time for us to transact,' said Pete Anevski, Chief Executive Officer of Progyny. The revolver is undrawn, and the Company has no planned use for the facility at this time. The Company's capital priorities, which include the evaluation of stock repurchases, the expansion of its product portfolio, investments in new distribution channels, and select acquisitions, remain unchanged. The Company also announced today that it expects its financial results for the quarterly period ending June 30, 2025, to be slightly better than the guidance ranges it provided during its first quarter earnings call. 'As the second quarter progressed, we were pleased to see that member activity has paced favorably as compared to our guidance,' continued Anevski. 'Accordingly, we now expect second quarter results for revenue, Adjusted net income and Adjusted EBITDA to be slightly above the ranges that we provided in May.' The company will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Thursday, August 7, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio replay of the call will be available through Thursday, August 14, 2025, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484. A live webcast and archive of the call will be available from the Events and Presentations section of the company's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2025, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2025; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2026 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words 'anticipates,' 'assumes,' 'believe,' 'contemplate,' 'continues, ' 'could,' 'estimates,' 'expects,' 'future,' 'intends,' 'may,' 'plans,' 'predict,' 'potential,' 'project,' 'seeks,' 'should,' 'target,' 'will,' and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the 'SEC'), including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports that we file with the SEC, which are available at and on the SEC's website at Forward-looking statements represent our management's beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons. Non-GAAP Financial Measures In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ('GAAP'), this press release includes the non-GAAP financial measure Adjusted EBITDA. Adjusted EBITDA is a supplemental financial measure that is not required by, or presented in accordance with, GAAP. We believe that this non-GAAP measure, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes. Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate Adjusted EBITDA, limiting its usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net income and our other GAAP results. We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes.
Yahoo
30-06-2025
- Health
- Yahoo
Reproductive Partners Medical Group Hosts Open House at New South Bay Fertility Center
TORRANCE, Calif., June 30, 2025--(BUSINESS WIRE)--Reproductive Partners Medical Group (RPMG), a nationally recognized leader in fertility care and a member of the Ivy Fertility network, invites the community to celebrate the opening of its new South Bay clinic at an Open House event on Friday, July 11th, from 5:30 to 8:00 PM. Located in the heart of South Bay in Torrance, California, the new state-of-the-art facility reflects RPMG's ongoing commitment to advancing fertility care through innovation, personalized treatment, and compassionate support. The Open House offers an opportunity for patients, referring providers, and members of the public to tour the clinic, meet the medical team, and learn about RPMG's comprehensive services: including IVF, IUI, fertility preservation, LGBTQ+ family building, and male fertility evaluations. "This space was designed with our patients in mind, from the calming atmosphere to the convenience of having our IVF lab, surgical center, and diagnostic services all under one roof," said Christina Westbrook, Chief Operating Officer of RPMG. "We're excited to open our doors and welcome the community into a space where hope, science, and support intersect." Guests will enjoy light refreshments, guided tours, and the chance to speak with RPMG physicians and staff about fertility options in a relaxed, educational setting. Attendees can also learn more about RPMG's upcoming offering: the Center for Male Fertility, opening this fall to provide expert care for male reproductive health. EVENT DETAILS:Date: Friday, July 11, 2025Time: 5:30 PM - 8:00 PMLocation: 23440 Hawthorne Blvd., Suite 230, Torrance, CA 90505RSVP appreciated: szuboff@ About Reproductive Partners Medical Group With over 30 years of experience and a reputation for clinical excellence, RPMG, a part of Ivy Fertility, provides advanced, evidence-based fertility treatments including IVF, IUI, third-party reproduction, and fertility preservation. The practice is committed to serving all individuals and families, regardless of marital status, gender identity, or sexual orientation with inclusive, expert care. For more information or to schedule a consultation, visit: About Ivy Fertility Ivy Fertility is globally recognized as pioneers and innovators in the field of advanced reproductive technologies, in-vitro fertilization, third-party reproduction, andrology, and fertility research. The Ivy Fertility network includes Dallas IVF, Fertility Associates of Memphis, Fertility Centers of Orange County, Idaho Fertility Center, IVF Fertility Center, Los Angeles Reproductive Center, Nevada Center for Reproductive Medicine, Nevada Fertility Center, Northern California Fertility Medical Center, NOVA IVF, Pacific Northwest Fertility, Reproductive Partners Medical Group, San Diego Fertility Center, Utah Fertility Center, and Virginia Fertility & IVF. By developing new procedures, achieving scientific breakthroughs, and teaching the latest techniques, Ivy Fertility upholds its commitment to successful outcomes and continually contributes to the development of the entire fertility community. The Ivy team is passionate about its family-building mission and works tirelessly each day to help patients become parents. View source version on Contacts Sara ZuboffMarketing Manager310-855-2229 x1419szuboff@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
27-06-2025
- Health
- Globe and Mail
Surrogacy4All Releases 2025 Rankings of Top Surrogacy Agencies, Championing Transparency, and Ethical Care for Intended Parents
People and couples who want to start a family may find it hard to figure out the complicated world of fertility services. There are more than 300 agencies in the US that offer gestational surrogacy, therefore it's really important to choose the correct one. Surrogacy4All, a well-known and doctor-owned agency, has proudly announced the release of its long-awaited 2025 Rankings of the Top 90 Surrogacy Agencies in the USA in answer to this challenge. Whether growing a family or helping others as an agency or clinic, the difference between a long wait and a smooth journey starts here. They reviewed 90+ U.S. surrogacy agencies and ranked them by what matters most: Fastest surrogate match times Cost transparency (no surprise fees) Success rates & medical oversight NYS licensing + FDA registration Only 4 agencies made it to Tier 1 — including those that are physician-led and fully certified. These are arranged alphabetically below: - Conceive Abilities - Family Inceptions International LLC - Happy Beginnings LLC - View the full 2025 rankings now: The new ranking is the first in the country to evaluate agencies offering commercial surrogacy based on critical criteria, including clinical success rates based on fertilization, surrogate match times, physician involvement, licensing, Google reviews, and surrogacy cost transparency. The initiative seeks to cut through marketing noise, revealing what truly matters to families: success, safety, and support. Dr. Naman Arya, Medical Coordinator of Surrogacy4All, stated, "Our mission is to make surrogacy accessible and ethical for all families. That starts with transparency. These rankings help intended parents, especially LGBTQ+ couples, navigate a confusing market and make informed decisions". Dr. Kulsoom Baloch, medical advisor at Surrogacy4All, emphasized, "Choosing a surrogacy agency is a leap of faith. Our goal was to bring trust and transparency to that journey by giving Intended Parents the data they need to make informed, confident choices". Surrogacy4All has emerged as a Tier 1 agency in these rankings, meeting the gold standard of being New York State licensed, FDA registered, and physician-led. Established in 2006, the agency boasts a 0-month match time, one of the fastest in the industry, and a 90%+ success rate for surrogacy journeys. The average journey cost for USA surrogacy is around $120,000, while overseas options start from $45,000. The organization also offers international options in Canada, Ghana, India, and more, each with distinct costs and regulations. The agency is owned and run by doctors. Therefore, the health and well-being of both the surrogate and the baby are always the most important. Surrogacy4All is open to all intended parents, including couples, LGBT parents, single men, and single women. They offer the best support and specialized advice. They connect intended parents with the best fertility clinics in the US. They have worked with hundreds of intended parents and over 100 IVF Centers around the country. They have been doing this for more than ten years and have a database of over 1,000 egg donors and surrogates. Testimonials highlight the agency's compassionate care, transparent pricing, and unwavering support. One client noted, "We searched far and wide—Googling everything from 'surrogacy agencies near me' to 'surrogacy programs near me' and 'best surrogacy agency near me.' After weeks of research, it became clear that Surrogacy4All offered the best value proposition in the entire country". The whole analysis, which puts more than 90 agencies into four groups, is available online. It includes graphics that compare services side by side, as well as estimates of costs, wait times, and success rates. These rankings should help intended parents avoid delays, scams, or high expenses, since agencies who don't have FDA or NYS certifications may not be able to prove that they are following the law. About Surrogacy4All: Surrogacy4All is a part of DGA, Inc., which is based in New York City. Since 2006, their physician-owned, FDA-registered, and New York State-licensed organization has helped hundreds of intended parents have successful surrogacy journeys in the US and Canada. Their goal is to make dreams come true by offering the best IVF and surrogacy services at low prices all over the world, while making sure that everyone gets the best care and service possible. Their affiliated websites are and Media Contact Company Name: Surrogacy4All Contact Person: Deepak Gulati Email: Send Email Phone: 2126617673 Address: 1148 Fifth Avenue 1C City: New York State: NY 10128N Country: United States Website:
